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Abstract
Background: The inflammatory properties of vein endothelium in relation to chronic venous disease (CVD) have been
poorly investigated. Therefore, new insights on the characteristics of large vein endothelium would increase our knowledge
of large vessel physiopathology.
Methodology/Principal Findings: Surgical specimens of veins were obtained from the tertiary venous network (R3) and/or
saphenous vein (SF) of patients affected by CVD and from control individuals. Highly purified venous endothelial cell (VEC)
cultures obtained from CVD patients were characterized for morphological, phenotypic and functional properties compared
to control VEC. An increase of CD31/PECAM-1, CD146 and ICAM-1 surface levels was documented at flow cytometry in
pathological VEC with respect to normal controls. Of note, the strongest expression of these pro-inflammatory markers was
observed in VEC obtained from patients with more advanced disease. Similarly, spontaneous cell proliferation and
resistance to starvation was higher in pathological than in normal VEC, while the migratory response of VEC showed an
opposite trend, being significantly lower in VEC obtained from pathological specimens. In addition, in keeping with a higher
baseline transcriptional activity of NF-kB, the release of the pro-inflammatory cytokines osteoprotegerin (OPG) and vascular
endothelial growth factor (VEGF) was higher in pathological VEC cultures with respect to control VEC. Interestingly, there
was a systemic correlation to these in vitro data, as demonstrated by higher serum OPG and VEGF levels in CVD patients
with respect to normal healthy controls.
Conclusion/Significance: Taken together, these data indicate that large vein endothelial cells obtained from CVD patients
exhibit a pro-inflammatory phenotype, which might significantly contribute to systemic inflammation in CVD patients.
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Introduction
Chronic venous disease (CVD) is a common problem that has a
significant impact on afflicted individuals and on the healthcare
system. Normal venous function requires the axial veins with a
series of venous valves, the perforating veins to allow communi-
cation of the superficial with the deep venous system, and the
venous muscle pumps. The dysfunction of any of the normal
structures may lead to the development of chronic venous
insufficiency [1]. Venous outcomes assessment tools have been
used to evaluate the severity of CVD, but little information is
available on the correlation between the currently used classifica-
tions, such as the clinical signs, etiology, anatomic distribution and
pathophysiology (CEAP), and the status of venous endothelial cells
in the afflicted veins.
The vascular endothelium acts as a barrier between tissue and
blood and regulates diverse functions, such as the local and central
hemodynamic and the exchange of nutrients and metabolites [2–
4]. Although it is recognized that the endothelium also plays
important roles in inflammatory diseases, atherosclerosis and
thrombosis [5–8], it should be emphasized that the endothelial
monolayer is made up by a diverse family of cells that, depending
on the location in the vascular tree, displays variable responses to a
variety of stimuli. While the endothelial phenotype in arteries is
characterized by the release of substances that influence vascular
smooth muscle tone, vessel diameter, and local blood perfusion
[9], the endothelium in post-capillary venules is specialized at
responding to local inflammatory stimuli by increasing its own
permeability toward macromolecules and by expressing molecules
that mediate recruitment of leukocytes to the sites of inflammation
[10]. Moreover, endothelial function is influenced by the
developmental origin of the cells as well as by local blood flow
dynamics [11,12]. In contrast to the endothelium of arteries and
venules, little is known about the endothelial function in large
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39543veins [13], although the responses of large vein endothelium play
important roles in clinical disease and it has been proposed that
destruction of venous valves leading to chronic venous congestion
is imposed by inflammatory mechanisms [14].
On these bases, we sought to elucidate the physiopathological
features of large vein endothelium at different stages of CVD. For
this purpose, we have set up an efficient system of endothelial cells
isolation from small pathological surgical specimens, which
allowed us to characterize ex-vivo pathological VEC cultures for
their phenotype, proliferation/survival, migration properties,
release of the pro-inflammatory cytokines osteoprotegerin (OPG)
[15] and vascular endothelial growth factor (VEGF), as well as for
the levels of activation of the transcription factor NF-kB.
Materials and Methods
Recruitment of patients and samples collection
Fifty-four patients affected by primary CVD with superficial
venous reflux were enrolled in this study and their main
demographic/clinical characteristics are reported in Table 1.
The surgical specimens were collected during surgery for
conservative and hemodynamic treatment of venous insufficiency
in ambulatory care. Briefly, target of the procedure was to perform
an effective treatment of CVD on ambulatory bases, sparing the
saphenous vein, restoring the saphenous drainage and permitting a
treatment of the recurrences by means of the same technique.
Surgical pathological specimens of veins were collected from the
tertiary venous network (referred as R3) and/or saphenous vein
(referred as SF). As control, SF VEC (n=5) were obtained from
Promo-cell (Heidelberg, Germany). Serum samples were collected
from primary CVD patients (n=32) at the time of CEAP disease
stage diagnosis and from sex- and age-matched healthy controls
(n=44). Venous blood samples from CVD patients and controls
were immediately centrifuged at 3000 rpm for 15 minutes and
serum was stored at 280uC in single-use aliquots. The procedures
followed were in accordance with the Declaration of Helsinki,
approved by the institutional review board (University-Hospital of
Ferrara) and all participant subjects gave written informed
consent.
Preparation of veins for scanning electron microscopy
After collection, venous segments intended for scanning electron
microscopy (SEM) analysis were rapidly cut longitudinally, washed
and placed in 2.5% glutaraldehyde for 24 hours at 4uC followed
by 2 hours of incubation in 1% osmium tetroxide at room
temperature. The samples were then treated with decreasing
concentration of ethanol ending with a passage on propylene
oxide. Finally, the samples were removed and covered with gold
through sputter deposition (S 150 Sputter Coater Edwards,
England) and examined under an AG-EVOH40 scanning electron
microscope (Cambridge, England).
VEC isolation and culture
The surgical fragments were removed from the collection pot,
placed in a sterile Petri dish and all visible fat and connective
tissues were removed by scalpel. The tissue was opened
longitudinally in order to expose the endothelium and washed
twice in PBS (Sigma Chemical Co, St Louis, MO). A 0.05%
collagenase type 1 solution (Worthington, Lakewood, NJ) was
added into a new Petri dish and the tissue was gently added on top
of the solution in order to put the endothelium in direct contact
with the enzyme solution. After 20 minutes of digestion at 37uC,
the tissue was turned face up and the endothelium was gently
scraped to detach endothelial cells. The containing-cells solution
was collected in a sterile 50 ml tube and the enzyme activity was
neutralized by adding fetal calf serum (Gibco BRL, Grand Island,
NY) to a volume ratio of 1:1. Cells were centrifuged and after two
washes in PBS they were seeded in EGM2 medium (Lonza,
Walkersville, MD) with 2% FBS and full supplements (EGM2
Bullet kit, Lonza) in multi-well plates (Corning Costar, Cambridge,
MA) coated with fibronectin (BD, Becton Dickinson, San Jose,
CA) at 5 mg/cm
2, as previously described [16]. Cultures were
placed in a 37uC humidified incubator at 5% CO2, washed after
72 hours and maintained under these conditions with medium
Table 1. Baseline characteristics of subjects.
n=54 %
Patient Age (years)
#35 4 7%
36–50 13 24%
$51 37 69%
Gender
Men/Women 13/41 24%/76%
Body mass index (kg/m2)
#20 3 6%
21–32 47 87%
$33 4 7%
Blood Pressure (mmHg)
Hypertensive patients (total) 15 28%
Normalized under treatment 13
Normotensive patients 39 72%
Family history
Yes/No 43/11 80%/20%
Relevant medical history 25 46%
DM2 1 2%
Impaired fasting glycaemia 2 4%
Atherosclerosis 3 5%
Cardiac Disease 2 4%
Hypercholesterolaemia 5 9%
Current smoker 12 22%
CEAP criteria
Clinical
C2 13 24%
C3 35 65%
C4 5 9%
C5 1 2%
Etiology
Primary 54 100%
Secondary 0 0%
Anatomy
Deep venous reflux 0 0%
Superficial venous reflux 54 100%
Deep and superficial reflux 0 0%
Pathophysiology
Reflux only 54 100%
Reflux and obstruction 0 0%
doi:10.1371/journal.pone.0039543.t001
Endothelial Cells in Chronic Venous Disease
PLoS ONE | www.plosone.org 2 June 2012 | Volume 7 | Issue 6 | e39543changed every 3 days until they attained confluence and were
designated P0 cultures. Cells were detached with trypsin-EDTA
solution (Lonza) and sub-cultured to approximately 80% conflu-
ence for cell banking and to perform in vitro experiments. For this
study, cells were used within passages 3 to 7.
Cytofluorimetric characterization of primary VEC
The purity of primary VEC cultures was evaluated by
multicolour flow cytometry analysis performed on a four lasers
BD FACSAria
TM II (BD Bioscience). Instrument parameters were
set up and monitored as described below. In brief, BD
TM
Cytometer Setup & Tracking Beads were used to define the
cytometer’s initial baseline status (the voltage tolerance range).
Once these baseline measurements were defined, the Cytometer
Setup and Tracking Beads were subsequently used to run day-to-
day cytometer performance checks. Experimental voltages were
established by using BD
TM CompBeads labelled with the
antibodies used for the experiments. Cells were detached with
trypsin-EDTA, washed and 5610
5 cells were resuspended in
200 ml of PBS containing 1% BSA (Sigma-Aldrich) and incubated
30 minutes at 4uC with the following anti-human endothelial-
defining antibodies (Ab): FITC-conjugated anti-CD146 (Miltenyi
Biotec, Gladbach, Germany, Clone 541-10B2), Horizon V450-A-
conjugated anti-CD144 (BD, Clone 55-7H1), PE-A-conjugated
anti-CD31 (Miltenyi Biotec, Clone AC128), Alexa Fluor 647-A-
conjugated anti-CD105 (BD, Clone 266), PE-Cy7-A-conjugated
anti-CD34 (BD, Clone 581), APC-H7-A-conjugated anti-CD45
(BD, Clone 2D1) and Horizon v500-A-conjugated anti-CD14
(BD, Clone M5E2). Data files were collected and analysed using
the FACSDiva software program (version 6.1.3; BD) and displayed
as single histogram colours and two-colours dot plots to measure
the proportion of the single-positive or double-positive cells. Only
cell cultures characterized by endothelial cell purity greater than
90% (n=21), as evaluated by multicolour flow cytometry analysis,
were used for subsequent studies. At different in vitro passages,
VEC cultures were analysed by flow cytometry using the following
Abs: FITC-conjugated anti-CD146 (BD), PE-A-conjugated anti-
CD31 (BD), PE-A-conjugated anti-CD105 (BD, clone 266), FITC-
conjugated anti-ICAM-1 (R&D, Minneapolis-MN, Clone BBIG-
I1) and FITC-conjugated anti-VCAM (R&D, Clone BBIG-V3).
Non-specific fluorescence was assessed by incubation with isotype-
matched conjugated mAbs. In some experiments, the degree of
apoptosis on detached endothelial cells was analysed by propidium
iodide/annexin-V staining performed as previously described
[17,18].
Proliferation and migration assays
Cell proliferation and migration were performed using the DP
version of the xCELLigence real time cell analyzer RTCA (Roche
Diagnostics, Mannheim, Germany), which records changes in
impedance (reported as a cell index-CI) over a prolonged time
course in a non-invasive system. All data were then analysed using
Figure 1. In situ morphological characterization of large vein endothelium. Morphological investigation of endothelium obtained from
control and CVD (from C2 to C4 stages) veins was performed by SEM. A representative panel composed of images from 2 control specimens and 6
pathological veins (2 for each CEAP stage) is shown. In C2-, C3- and C4-veins, luminal pathological vessel surfaces were covered by endothelial cells
characterized by an irregular orientation and several morphological abnormalities, such as: discontinuous surface of the endothelium (arrowheads),
which increases with the severity of the disease, presence of plaques covering the endothelial surface (asterisks) and/or presence of numerous
microvilli (arrow). Red cells adhering to endothelium were frequently observed (left C3 images).
doi:10.1371/journal.pone.0039543.g001
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PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e39543Figure 2. Isolation and phenotypic characterization of large vein endothelial cells. Cells isolated from surgical specimens were
characterized in-vitro by morphological assessment (A) and multiparametric flow cytometry analysis (B). In A, cell morphology was examined by
using phase-contrast microscopy. VEC cultures were characterized by regular polygonal shape and dimensions and uniform monolayer. On the other
hand, non-VEC cultures appeared with a fibroblast-like morphology characterized by elongated shapes and growing in an uneven manner.
Representative images of VEC and non-VEC cultures, at two different in vitro passages (p=0 and p=3), are shown. Left panels: 10X, original
magnification; right panels: 20X original magnifications. In B, multiparametric flow cytometry analyses were performed with a specific panel of
endothelial cells defining antibodies. VEC were defined as CD146
+/CD144
+/CD31
+/CD105
+/CD34
+/CD45
2/CD14
2 while non-VEC displayed a more
variable and random pattern of antigens expression. Two representative multiparametric flow cytometry analysis panels of a non-VEC and pure VEC
cultures are shown as two-colors dot plots.
doi:10.1371/journal.pone.0039543.g002
Figure 3. Differential phenotype between control and pathological VEC. Surface expression of CD31 and CD146 was evaluated by flow
cytometry in either pathological and control-VEC. In A, colored histograms represent cells stained with monoclonal antibodies specific for the
indicated antigens and white histograms represent background fluorescence obtained by staining the same cells with isotype-matched control
antibodies. Representative panels for control, C2- and C3-VEC are shown. In B, the expression levels of the indicated antigens were determined for all
VEC samples (8 C2-VEC, 13 C3-VEC and 5 control-VEC) by flow cytometry analysis and expressed as mean fluorescence intensity (MFI). Horizontal bars
are median, upper and lower edges of box are 75th and 25th percentiles, lines extending from box are 10th and 90th percentiles. *P,0.05 compared
to control VEC.
doi:10.1371/journal.pone.0039543.g003
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proliferation assay the background impedance of RTCA DP E-
Plates 16 was performed using the standard protocol provided in
the software with 100 mL of EGM-2. Endothelial cells were seeded
in quadruplicate at three different concentrations in fibronectin-
pre-coated wells with 100 mL of complete (2% FBS and cytokines/
growth factors) EGM2 and left to equilibrate at room temperature
for 30 minutes. The CI of the proliferating cells was recorded up
to 72 hours and data were expressed as mean of CI normalized to
the CI recorded at 4 hours. For assays under starvation cells were
allowed to adhere and proliferate in complete EGM2 for 24 hours
before changing the medium with EBM2 without serum and
cytokines/growth factors. The CI of the cells was recorded up to
72 hours after the beginning of the starvation and data were
expressed as mean of CI normalized to the CI recorded at
24 hours.
Migration experiments were performed using fibronectin-pre-
coated RTCA DP CIM-Plates 16. Cells were seeded in the upper
chamber in quadruplicate at three different concentrations and left
to equilibrate at room temperature for 30 minutes. Migration
kinetics were analyzed in the absence or presence of 10% FBS in
the bottom chamber and recorded up to 6 hours.
Figure 4. Analysis of ICAM-1 and VCAM expression in control and pathological VEC. In A–C, surface expression of ICAM-1 antigen was
evaluated by flow cytometry in either pathological and control-VEC. In A, colored histograms represent cells stained with monoclonal antibodies
specific for the indicated antigens and white histograms represent background fluorescence obtained by staining the same cells with isotype-
matched control antibodies. A representative panel for control-, C2- and C3-VEC is shown. In B, the expression levels of ICAM-1 were determined for
all VEC samples (8 C2-VEC, 13 C3-VEC and 5 control VEC) by flow cytometry analysis and expressed as mean fluorescence intensity (MFI). *P,0.05
compared to control VEC. In C, comparative analysis of ICAM-1 surface expression, reported as MFI, at different VEC passages. In D–E, pathological
and control-VEC cultures were exposed to TNF-a for 18 hours before ICAM-1 and VCAM surface expression analysis by flow cytometry (D), and mRNA
levels analysis by quantitative RT-PCR (E). In D, two representative panels are shown: dotted histograms represent background fluorescence obtained
by staining the same cells with isotype-matched control antibodies. The expression levels of ICAM-1 and VCAM, determined for all VEC samples by
flow cytometry analysis upon TNF-a stimulation, are expressed as mean fluorescence intensity (MFI). In E, mRNA expression levels of ICAM-1 and
VCAM were determined both in unstimulated and TNF-a-stimulated VEC cultures. Results from amplifications, done in duplicate, are expressed as
arbitrary units, after normalization for the housekeeping gene. Horizontal bars are median, upper and lower edges of box are 75th and 25th
percentiles, lines extending from box are 10th and 90th percentiles.
doi:10.1371/journal.pone.0039543.g004
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PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e39543Figure 5. Differential migration kinetics between control and pathological VEC. Control and pathological VEC cells were seeded at
2.5x10
4 cells in fibronectin-coated 16 wells CIM-plates, and migration kinetics were analyzed in the absence or presence of 10% FBS in the bottom
chamber and recorded by the xCELLigence real time cell analyzer. Cell migration was evaluated for all VEC cultures by using the recording changes in
impedance and was expressed as cell index (CI). In A, representative panels of control-VEC, C2-VEC and C3-VEC migration, expressed as CI mean6SD
(with samples assayed in quadruplicate), are shown. Blue lines: specific migration through FBS gradient; red lines, background migration. In B,
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Expression levels of ICAM-1 and VCAM were evaluated in
VEC cultures either left untreated or treated with 2 ng/ml of
TNF-a (R&D System) for 18 hours by quantitative RT-PCR.
Total RNA was extracted from cells by using RNeasy Plus mini kit
(Qiagen, Hilden, Germany) according to the supplier’s instruc-
tions. The quality of the total RNA preparation was verified by
agarose gel and, when necessary, further purification was
performed with the RNeasy cleanup system (Qiagen) to remove
chromatin DNA. Total RNA was transcribed into cDNA, using
the QuantiTect Reverse Transcription kit (Qiagen). Analysis of
ICAM-1 and VCAM gene expression was carried out using the
SYBR Green real-time PCR detection method with the SABios-
ciences RT2 Real-Time
TM Gene expression assays, that include
specific validated primer sets and PCR master mixes (SABios-
ciences, Frederick, MD), as previously described [19]. All samples
were run in triplicate by using the real time thermal analyzer
rotor-gene
TM 6000 (Corbett, Cambridge, UK). Expression values
were normalized to the housekeeping gene POLR2A amplified in
the same sample.
Assay for NF-kB DNA binding
Baseline levels of active NF-kB were measured in protein cell
extracts using the TransAM NF-kB p65 kit (Active Motif,
Rixensart, Belgium), which evaluates the form of NF-kB able to
bind specifically to an oligonucleotide containing the NF-kB
consensus site (59-GGGACTTTCC-39) attached to a 96-well
plate. Assays were performed in duplicates, according to the
manufacturer’s instructions. NF-kB DNA binding activity was
determined as absorbance values measured by using an Anthos
2010 ELISA reader (Anthos Labtec Instruments Ges.m.b.H,
Salzburg, Austria). Increase in fluorescence was linear over extract
concentration.
Enzyme-linked immunosorbent assay (ELISA) for OPG
and VEGF measurement
Serum samples and endothelial culture supernatants were
analysed for the pro-inflammatory cytokines OPG (Alexis
Biochemicals, Lausen, Switzerland) and VEGF (R&D System)
by using ELISA kits according to the manufacturer’s instructions
and as previously described [20]. Measurements were done in
duplicates and the results were read at an optical density of
450 nm using an Anthos 2010 ELISA reader (Anthos Labtec
Instruments Ges.m.b.H). Sensitivity of the OPG assay was 2.8 pg/
ml, the intra- and inter-assay coefficients of variation (CV) were
9% and ,10%, respectively. Sensitivity of the VEGF assay was
5 pg/ml, the intra- and inter-assay coefficients of variation (CV)
were 7% and ,9%, respectively.
Statistical analysis
Descriptive statistical were calculated. For each set of experi-
ments, values were reported either as means6SD or box plots
were used to show the median, minimum and maximum values,
and 25th to 75th percentiles. The results were evaluated by using
Student’s T and the Mann–Whitney rank-sum tests, when
appropriate. Statistical significance was defined as p,0.05.
Results
In situ morphological characterization of large vein
endothelium
In order to start to characterize the properties of venous
endothelial cells obtained from patients affected by different stages
of CVD, we have collected surgical specimens from 54 patients,
with clinical signs of CVD to a leg with or without an ulcer (clinical
class 2–5 according to the CEAP classification; Table 1),
undergoing surgery. Surgical specimens of 3–9 mm of length
were processed for in situ morphological analysis and/or endothe-
lial cell culture isolation based on the sample size. As shown in
Figure 1, at morphological analysis, performed by SEM, normal
vein (Control) showed a virtually intact endothelial layer. This
appearance changed completely in disease specimens that
displayed a progressive loss of the integrity of the endothelial
monolayer as evidenced by craters or cavities and partially
detached cells. At higher magnifications we could observed the
presence of plaques covering the endothelial surface, red cells
sticking to the endothelium and/or presence of numerous
microvilli covering the endothelial surface that might reflect
increased permeability of dysfunctional endothelial cells
(Figure 1).
Isolation and phenotypically characterization of large
vein endothelial cells
Among the 54 surgical specimens, the quality and the size of the
specimens have allowed endothelial cell isolation in 47 out of 54
specimens. The morphology of the cultures has been examined
regularly during the expansion process in order to identify the
nature of the isolated cells and to confirm the healthy status of the
cultures. Typically, one week after seeding it was already possible
to distinguish between predominantly VEC and non-VEC
cultures. As shown in Figure 2A, VEC were polygonal in shape
with regular dimensions; they grew uniformly attached to the
substrate and the potential contamination of other cell types
(presumably stromal cells) that characterized the first days of
culture normally disappeared within few in vitro passages due to the
predominance of endothelial cells. On the contrary, non-VEC
were normally fibroblastic (or fibroblast-like) cells, bipolar or
multipolar, showing elongated shapes and growing attached in
either uniform way or distinct clusters (Figure 2A). In parallel, a
multicolor flow cytometry protocol was used to characterize VEC
cultures based on the exclusion of cells expressing CD45 (a
hematopoietic marker) and CD14 (expressed mainly by macro-
phages). VEC cultures were positive for CD146, CD144, CD31,
CD105 and CD34 and, as far as the detection of contaminant
hematopoietic cells within the endothelial monolayers, the low
levels of CD45
+ cells observed in cultures at first passage tended to
decrease during the in vitro expansion (Figure 2B). The non-VEC
cultures showed a more variable immune-phenotype going from a
complete negativity for the expression of the selected markers
(Figure 2B), to random levels of expression for single antigens. No
relationship was observed between the age of patients and the
efficiency of VEC isolation. Once we have defined the isolated
cells as VEC (based on the multiparametric phenotypic charac-
terization), cultures were expanded and after two-three passages,
cells were further characterized for culture purity. As result, 21
VEC cultures obtained from patients affected by CVD (8 C2 and
13 C3) were selected on the base of purity.90%, as defined by
horizontal bars are median, upper and lower edges of box are 75th and 25th percentiles, lines extending from box are 10th and 90th percentiles.
*P,0.05 compared to control VEC.
doi:10.1371/journal.pone.0039543.g005
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+/CD105
+/CD146
+/CD144
+/CD45
2/CD14
2, and used
for the subsequent in vitro functional and molecular investigations.
CD34 marker was not used in this stage of VEC culture
characterization since it tends to be variably lost during the
culture passages.
VEC exhibit differential phenotype and in vitro migratory
and proliferation activities
At the time of the in vitro functional assays, pathological VEC
(n=21) and control VEC cultures (n=5) were characterized for
the surface expression of the following molecular markers: CD146,
CD31, CD105, VCAM, ICAM-1. Even though the percentage of
positive cells expressing CD31 and CD146 was .90% in all VEC
cultures, pathological VEC showed a significantly (p,0.05)
increased expression of CD31 and CD146 compared to control
VEC with a growing trend in C3-VEC as compared to C2-VEC
(Figure 3A–B). On the other hand, CD105 was highly expressed
(.90%) in all VEC cultures without showing significant differ-
ences among pathological and normal cultures (data not shown).
In addition, also the surface expression level of ICAM-1, analysed
by flow-cytometry (Figure 4A–C), was significantly (p,0.05)
higher in C3-VEC compared to C2-VEC and normal-VEC. On
the other hand, VCAM was undetectable at the surface levels in
unstimulated cultures, although similarly to ICAM-1, its expres-
sion was significantly induced both at protein (Figure 4D) and
mRNA (Figure 4E) level in response to TNF-a.
We next analysed biological key functions of endothelial cells:
the migratory and the proliferative/survival capabilities. The
directed migration response of VEC toward serum (10% FCS) was
investigated using the real-time and label-free monitoring of cell
migration based on electrical impedance real-time cell analysis
(RTCA). As shown in Figure 5A–B, the migration of C3- and
C2-VEC, recorded 6 hours after cell plating, was comparable in
terms of cell index. On the other hand, control VEC showed a
significantly (p,0.05) higher migration ability compared to
pathological VEC (Figure 5B).
In contrast to the migration data, pathological VEC showed a
significantly (p,0.05) higher spontaneous proliferation activity
when cultured in complete (supplemented with serum and growth
factors) medium, anticipated in C3-VEC (24 hours), with respect
to control-VEC (Figure 6A–B). Even in starvation conditions
(72 hours in the absence of serum and growth factors), the cell
index of C3-VEC was significantly (p,0.05) higher than control
VEC, indicating a higher resistance to growth factors deprivation
(Figure 6C).
C3-VEC are characterized by higher levels of NF-kB
activity and by increased release of the pro-inflammatory
cytokines OPG and VEGF
In order to start to dissect the molecular mechanism underlining
the pro-inflammatory phenotype of pathological VEC, we assessed
the activation levels of NF-kB, by analysing VEC cell lysates for
binding activity of p65/RelA to an oligonucleotide containing the
kB consensus site, in TransAM assays (Figure 7A). Of note, a
significant (p,0.05) higher baseline NF-kB activity was measured
in C3- with respect to C2- and control-VEC. Consistently, both
OPG and VEGF, which are transcriptional targets of NF-kB
[21,22] and represent important mediators of endothelial inflam-
mation and/or angiogenesis, were released at significantly
(p,0.05) higher levels in the culture supernatant of pathological
VEC with respect to control-VEC (Figure 7B). Moreover, since
both OPG and VEGF exert pro-survival and proliferative effects
in endothelial cells, it is likely that both cytokines contribute to the
increased proliferation activity of C3-VEC observed in both
complete medium and under starvation (Figure 6A–C).
In the last group of experiments, we have analysed whether the
elevation of OPG and VEGF observed in the culture supernatants
of C3-VEC might have a systemic correlate. For this purpose, we
have measured the serum levels of OPG and VEGF in a group of
C2 and C3 patients as well as in sex and age-matched normal
controls. As shown in Figure 7C, CVD-patients showed
significantly (p,0.05) higher levels of circulating OPG and VEGF
with respect to normal controls.
Discussion
How the inflammatory properties of vein endothelium stand in
relation to CVD was completely unknown. Therefore, we
reasoned that data elucidating the characteristics of large vein
endothelium would increase our knowledge of large vessel
physiopathology. By analysing 21 pure pathological VEC cultures,
derived from C2 and C3-stage of disease according to the CEAP
classification, in comparison with 5 normal VEC, we were able to
demonstrate that pathological VEC showed distinct in vitro
characteristics with respect to normal VEC: i) increased surface
expression of CD146, CD31/PECAM-1 and ICAM-1; ii)
increased cell proliferation activity; iii) increased survival in
starvation conditions, iv) decreased spontaneous migration; v)
increased release of OPG and VEGF. Importantly, at molecular
levels, pathological VEC were characterized by an increased
baseline transcriptional activity of NF-kB with respect to control
VEC. Moreover, the increased in vitro release of OPG and VEGF
by pathologic VEC showed a systemic correlate represented by
elevated serum levels of OPG and VEGF in C3 and C2 patients
with respect to sex- and age-matched controls.
It is noteworthy that the surface markers significantly up-
regulated in pathological versus normal VEC (CD146, CD31/
PECAM-1 and ICAM-1) have been involved in different aspects of
the inflammatory response of endothelial cells. In particular,
CD146 and its soluble form regulate monocyte trans-endothelial
migration [23] and promote angiogenesis [24]. CD31/PECAM-1
is vital to the regulation of inflammatory responses, as it has been
shown to serve a variety of pro-inflammatory functions, such as the
facilitation of leukocyte trans-endothelial migration and the
transduction of mechanical signals in endothelial cells emanating
from fluid shear stress [24–26]. However, CD31/PECAM-1 has
also been involved in the maintenance of vascular barrier integrity.
Finally, ICAM-1 is known to promote recruitment of leukocytes,
platelets, and erythrocytes to the vein wall [27,28].
Taken together, these data are suggestive of a pronounced pro-
inflammatory profile in CVD endothelial cells, which correlates
Figure 6. Differential proliferation kinetics between control and pathological VEC. Control and pathological VEC cells were seeded in
fibronectin pre-coated 16 wells E-plates and monitored using the xCELLigence real time cell analyzer (RTCA). In A–B, cell proliferation was evaluated
for all VEC samples and was expressed as cell index (CI) after normalization to the CI recorded at 4 hours. In A, representative panels of control-VEC,
C2-VEC and C3-VEC proliferation, expressed as CI mean6SD (with samples assayed in quadruplicate), are shown. In B, horizontal bars are median,
upper and lower edges of box are 75th and 25th percentiles, lines extending from box are 10th and 90th percentiles. *P,0.05 compared to control
VEC. In C, data were generated by monitoring cell index in conditions of starvation (72 hours of serum and growth factor deprivation). *P,0.05
compared to control VEC.
doi:10.1371/journal.pone.0039543.g006
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cells. In keeping with this hypothesis, the enhanced release of OPG
by C3-VEC is an event coherent with a more advanced
inflammatory condition in C3.C2.normal endothelial cells. In
fact, we have previously demonstrated that part of the pro-
inflammatory activity of OPG is due to its ability to act as a bridge
between leukocytes and endothelial cells [16]. Our current
findings are in line with previous studies indicating that specific
inflammatory mediators are associated with time- and pattern-
dependent healing progression in CVD [29]. In addition, it has
been shown that endothelial dysfunction is present in varicose
veins and that this anomaly can be reverted by cardiovascular
protecting agents [30]. In the context of our study, it is noteworthy
that an association has been described between symptoms of CVD
in the lower extremities and cardiovascular risk factors [31–33]. In
particular, in one study, after excluding the effect of age, CVD
symptoms were still strongly associated with a history of coronary
artery disease and a cluster of cardiovascular risk factors that
included higher values of body mass index, waist circumference
and serum triglycerides [33]. These results support the hypothesis
that there is an overlap between atherosclerotic and venous
disorders. In this respect, it is noteworthy that several studies have
previously demonstrated that elevated circulating levels of OPG,
as well as of VEGF, represent a risk factor for cardiovascular
disease [34–38].
In conclusion, we have established that endothelial cells
obtained from large veins affected by an intermediate degree of
CVD display a shift towards a pro-inflammatory phenotype. Of
note, several pro-inflammatory markers (CD31, CD146, ICAM-1
and OPG) showed a gradient from normal to pathological VEC,
which was related to the stage (C2 or C3) of the disease. In
addition, the soluble inflammatory markers OPG and VEGF were
increased not only in the culture supernatant, but also in the
general circulation, suggesting that VEC significantly contribute to
promote systemic inflammation.
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